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Background
HIV-1 protease is an important virus protein that is a tar-
get of both antiretroviral therapy and cellular immune
response, which can both act as inducers of mutation.
Here, we investigated the T cell recognition of autologous
HIV-1 protease epitopes.
Methods
Seventy-two HIV-1+ patients undergoing protease inhibi-
tor (PI) therapy were recruited. We synthesized three pep-
tides from HXB2 strain protease (wild-type) and 32
additional peptides from the same regions, which encom-
passed the most frequent PI-induced mutations in Brazil.
PBMC from those patients were analyzed by the CFSE
dilution assay to detect proliferating CD4+ and/or CD8+
T cell responses against each of the 35 protease peptides.
Pol protease HIV-1 genomic regions were sequenced
using internal primers with the ABI Prism Dye Terminator
Cycle Sequencing Reaction Kit in an automated
sequencer.
Results
Variable profiles of recognition of wild-type and corre-
sponding mutant epitopes were found. To analyse these
profiles, we took into consideration only those patients
whose autologous protease sequence included a 100%
match with one of the tested peptides. Only 21% such
patients recognized a peptide identical to its own autolo-
gous protease sequence. Paradoxically, the most frequent
pattern of recognition (49%) was the recognition of pep-
tides dissimilar to autologous protease sequences, with
failure to recognize peptides identical to autologous
sequences. This indicated that the absence of recognition
of autologous sequences was not due to spurious
sequence variations not included in peptides, but rather
by the actual absence of recognition of such matching
autologous peptides. Bona fide crossreactivities were a rel-
atively rare event, occurring in 18% of the patients.
Conclusion
Recognition of sequences dissimilar to the autologous
sequence occurred in the majority of patients. It is possi-
ble that the observed immune responses were developed
to an antigenic sequence which was common in the past,
and which then underwent an escape or drug-induced
mutation.
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